Evidence-based guides on metabolic health, hormones, peptides, and longevity. Understand your biology and make better decisions.
See how your biomarkers, risk factors, and goals translate into next steps.
Most adults discover metabolic dysfunction long after symptoms appear. The clinical criteria for metabolic syndrome give you a framework for spotting it years earlier — using markers your annual physical already measures.
Read article →
The "normal" T range a typical lab uses spans from age 20 to age 80. What's normal for the population isn't necessarily optimal for you.
Read article →
What the published research actually says about each compound — separated from the social-media noise. Where evidence is strong, where it's preliminary, and where it's mostly anecdote.
Read article →
The threshold for "pre-diabetes" sits at 5.7 — but the disease process starts earlier. Here's what the trajectory typically looks like, and why early action changes the curve.
Read article →Most people who develop type 2 diabetes, heart disease, or stroke didn't get there overnight. They got there over a decade or two of slowly drifting metabolic markers — markers that were already on the lab panel of their annual physical, but that nobody flagged because each one, alone, was "still in range." Metabolic syndrome is the recognition that these markers cluster, and that the cluster itself is the disease, long before any individual marker becomes a diagnosis.
Metabolic syndrome isn't a single disease. It's a clinically-defined cluster of five common findings that, when three or more co-occur, identify someone whose risk for cardiovascular disease and type 2 diabetes is meaningfully elevated — even if no single finding has crossed into a "real" diagnosis yet.
The criteria most clinicians use come from the National Cholesterol Education Program's Adult Treatment Panel III (ATP III), updated in 2005. The framework asks: looking at the most common modifiable risks, how many is this person carrying?
The threshold is ≥40 inches for men, ≥35 inches for women. Waist measurement is preferred over BMI because central fat — the kind that sits around the abdominal organs — is metabolically more disruptive than fat distributed elsewhere. Two people with the same BMI can have very different metabolic profiles depending on where the fat lives.
If waist measurement isn't available, BMI ≥30 is sometimes used as a proxy. It's imperfect: a muscular athlete can carry BMI 31 with normal waist circumference, and a sedentary office worker can carry BMI 26 with abdominal obesity. Waist is the more reliable signal.
Triglycerides are how your body stores excess calories — particularly excess refined carbohydrates and alcohol — for later use. Elevated fasting triglycerides indicate that the system is overwhelmed: more incoming energy than current capacity to store or burn it, often combined with insulin resistance.
Triglycerides above 150 are a strong signal of metabolic strain even when other lipid numbers (LDL, total cholesterol) look fine. Some clinicians weight this marker more heavily than the formal criteria do, because high triglycerides are tightly correlated with the underlying insulin resistance that drives the rest of the syndrome.
The threshold is <40 mg/dL for men, <50 mg/dL for women. HDL is the lipoprotein that ferries cholesterol away from artery walls. Low HDL doesn't directly cause cardiovascular disease, but it's a reliable marker of metabolic dysfunction — the same processes that drive insulin resistance and high triglycerides also suppress HDL production.
Low HDL is one of the markers that's hardest to move with diet alone. Aerobic exercise, smoking cessation, and weight loss all help; statins typically don't.
The metabolic syndrome BP cutoff (≥130/85) is intentionally lower than the cutoff for clinical hypertension diagnosis. The point is to capture people whose pressure is rising even before they meet the criteria for a "BP diagnosis." Blood pressure rising over time tracks tightly with insulin resistance and visceral fat — both upstream drivers in the same cluster.
Note: if someone is taking antihypertensive medication, that counts as meeting the criterion, regardless of what the current reading is. The medication is treating the underlying condition; the underlying condition is what the syndrome is measuring.
The original criterion is fasting glucose ≥100 mg/dL. In practice, many clinicians substitute hemoglobin A1c ≥5.7 — the "pre-diabetes" range — because A1c reflects average glucose over 2-3 months and isn't sensitive to whether the patient actually fasted properly before the lab draw.
This marker is the closest one to becoming a "real" diabetes diagnosis. By the time fasting glucose hits 126 or A1c hits 6.5, the person has type 2 diabetes by definition. Before that, the trajectory has typically been visible on labs for 3–7 years if anyone was watching.
The "three of five" rule isn't arbitrary. Cohort studies (the most-cited being the third National Health and Nutrition Examination Survey, NHANES III) found that the risk for cardiovascular events and progression to type 2 diabetes climbed sharply at the 3-criterion threshold, while people with only one or two criteria had risk profiles much closer to people with zero criteria.
So the cluster matters more than any single marker. Someone with elevated triglycerides alone has a different prognosis than someone with elevated triglycerides plus low HDL plus rising glucose — the second person is on a metabolic trajectory the first person isn't.
For someone meeting the ATP III definition, the published natural history (Lakka et al., JAMA 2002, and subsequent meta-analyses) is roughly:
None of these are "you will get this." They're statistical elevations of risk over baseline. People with metabolic syndrome do not all progress to diabetes; people without it do not all stay disease-free. But the cluster moves the curves enough that early identification meaningfully changes the population-level outcomes.
The good news in the metabolic syndrome literature is that the cluster is responsive to intervention — usually more responsive than any single marker treated in isolation. Studies consistently show:
If you have access to your most recent annual physical labs, you already have most of what you need to estimate where you sit on this framework. Look for: waist circumference (or BMI as a proxy), fasting triglycerides, HDL, blood pressure, and either fasting glucose or A1c.
Count the criteria. If you're carrying three or more, the most useful next step is a conversation with your primary care provider — not because you have an emergency, but because the trajectory is real and acting on it earlier is meaningfully better than acting on it later.
Reach Peak Life's Longevity Score includes a metabolic syndrome screen as part of its scoring engine. If you'd like to see where your numbers land — and what the most modifiable lever in your particular profile is — the calculator takes about 5 minutes. Your data is processed entirely in your browser and isn't sent to any server unless you explicitly opt to receive your report by email.
5 minutes. Browser-only. Built around the same evidence base this article is.
Start your assessment →When men get a testosterone test, they're typically given a single number and told whether it's "normal" or "low." But what counts as "normal" depends on the reference range a particular lab uses — and most reference ranges are built by averaging values from men aged 18 to 80. That's a strange standard to apply to any individual person at any individual life stage.
A typical clinical reference range is calculated by drawing blood from a "normal" population — often a few hundred men of mixed ages — and reporting the values that fall between the 2.5th and 97.5th percentiles. Anything inside that band gets labeled "normal." Anything outside is "low" or "high."
The problem is whose blood is being averaged. Different labs use different source populations. Quest's adult male testosterone reference range is roughly 264–916 ng/dL. LabCorp's is 264–916. Some hospital labs use 280–1100. The variation between labs is real and isn't a rounding issue — it reflects genuinely different source populations and slightly different assay methods.
More importantly: a reference range built by averaging across a population that's getting older and heavier every year tells you very little about what optimal looks like for a healthy 35-year-old today.
The Endocrine Society's 2018 clinical guideline (Bhasin et al.) treats total testosterone below approximately 264 ng/dL as the threshold below which a hypogonadism workup is appropriate, but explicitly notes that symptoms must accompany the lab value — a low number alone is not a diagnosis. The guideline also notes that values in the lower end of the "normal" range (300–400 ng/dL) frequently produce symptoms in younger men whose physiology was previously running higher.
Observational studies of mortality (Yeap et al., 2014; Khaw et al., 2007) tend to find that the lowest all-cause mortality clusters between roughly 500–800 ng/dL, with risk rising on either side. This isn't strong enough evidence to call a target — confounding is severe in observational testosterone work — but it's worth knowing the published curves don't peak at 264.
The major guidelines all converge on the same point: testosterone therapy isn't indicated by lab values alone. Symptoms that consistently track with low testosterone include reduced libido, erectile dysfunction, loss of morning erections, decreased muscle mass and strength, increased body fat, depressed mood, fatigue, and reduced exercise tolerance. None of these are specific — sleep apnea, depression, hypothyroidism, and chronic stress all produce overlapping symptoms — which is why a workup is required, not just a single TT draw.
The flipside also matters: a man with a testosterone value of 320 who feels fine and has good function probably doesn't need therapy, even though his number is in the lower end of the range. Treating numbers without symptoms is one of the things responsible TRT programs explicitly avoid.
Reach Peak Life's eligibility criteria — applied by independent licensed prescribers, not by Reach Peak Life itself — match the major guideline standards: total testosterone ≤250 ng/dL on two separate morning blood draws, OR ≤300 ng/dL with documented symptoms. Two morning draws because testosterone fluctuates significantly within a single day (highest in the morning, lowest in the evening) and across days. A single low value is rarely enough to make a clinical decision.
Above the threshold, therapy is generally not indicated. This is true even for men with symptoms — the appropriate next step is usually to investigate the symptoms (sleep, weight, stress, thyroid, mood) rather than to start hormone replacement.
The literature is consistent that several non-pharmaceutical levers move testosterone meaningfully:
None of these are quick fixes. But all of them are zero-risk and frequently move the number enough to remove the question of whether therapy is actually needed.
Most men assume "low testosterone" means one fix: testosterone replacement. The actual clinical landscape is broader. Endogenous testosterone production runs through a feedback loop called the hypothalamic-pituitary-gonadal (HPG) axis — the hypothalamus releases GnRH, the pituitary releases LH and FSH in response, and LH stimulates the testes to produce testosterone. The body monitors circulating testosterone and estradiol and adjusts upstream signaling to keep the system in balance.
Different therapies act on different parts of this axis, with meaningfully different downstream effects. Understanding which therapy targets which part of the loop is what makes "what's the right approach for me" answerable rather than defaulting to TRT for every patient.
Exogenous testosterone — given as injection, cream, or pellet — restores circulating levels directly. Because the body senses the elevated testosterone, it down-regulates upstream LH and FSH signaling. Endogenous production drops, the testes shrink modestly over time, and spermatogenesis (sperm production) is reduced or suppressed entirely.
For men past their reproductive years, or men who have completed their families, this is usually a non-issue and TRT remains the most predictable and best-studied option, with decades of clinical use and the recent TRAVERSE cardiovascular safety data (Lincoff et al., 2023). For men under 40 who may want children, the fertility consequence is the most important thing to discuss before starting.
A second class of therapy works by stimulating the body's own production rather than replacing it. Clomiphene citrate, originally developed for ovulation induction in women, blocks estrogen-receptor feedback at the hypothalamus. With less estrogen feedback, the hypothalamus increases GnRH, the pituitary releases more LH and FSH, and the testes produce more endogenous testosterone. The HPG axis stays active. Spermatogenesis is preserved.
Enclomiphene is the trans-isomer of clomiphene — the component of the molecule responsible for most of the testosterone-raising effect, separated from the zuclomiphene isomer associated with side effects (mood changes, vision disturbances). In published trials (Wiehle et al., 2014; Kim et al., 2016), enclomiphene raised total testosterone meaningfully in men with secondary hypogonadism while preserving sperm count — the latter is the key clinical distinction from TRT. Enclomiphene is currently used off-label for symptomatic hypogonadism in men who want to preserve fertility, and is available through 503A compounding pharmacies. It is not FDA-approved as a commercial product for hypogonadism, though it has been extensively studied and was reviewed (but not approved) by the FDA in 2016.
SERMs work best for secondary hypogonadism — where the testes are still functional but upstream pituitary signaling is low. They are less effective for primary hypogonadism, where the testes themselves are not responding to LH, and a check of LH and FSH alongside total and free testosterone is what distinguishes the two scenarios on lab work.
hCG is a hormone that mimics LH directly, bypassing the hypothalamus and pituitary to stimulate the testes. It is sometimes used as monotherapy in younger men prioritizing fertility, and is sometimes added to TRT regimens specifically to maintain testicular function and spermatogenesis during treatment. It is administered by injection.
The right therapy depends on the man's age, fertility goals, baseline labs, and which part of the HPG axis is the actual bottleneck. A 28-year-old with secondary hypogonadism who wants children in five years has a different optimal protocol than a 55-year-old whose family is complete and whose primary symptoms are fatigue and low recovery.
A licensed prescriber working from a full lab panel — including LH and FSH alongside total testosterone, free testosterone, estradiol, and SHBG — is the only way to make this decision well. The presence of multiple options is not a marketing pitch for any one of them. It's a recognition that "low T" describes a symptom and a number, and that the most appropriate treatment depends on what's actually causing them.
If you've already addressed the lifestyle factors above and your numbers are still consistently low — or you have documented symptoms with values in the 250–300 range — Reach Peak Life's hormone optimization program connects you with independent prescribers for evaluation. Therapy is prescribed only when the criteria above are met and only with ongoing lab monitoring.
Provider-supervised hormone therapy for men whose labs and symptoms meet clinical criteria — protocol selected by your prescriber based on your goals, fertility considerations, and baseline labs. Quarterly monitoring included.
Learn about Hormone Optimization →Peptide therapy moved from niche bodybuilding circles to mainstream wellness marketing in roughly five years. Not all of the claims kept up with the evidence. Here's what the published research actually says about each of the five compounds Reach Peak Life's longevity protocols include — separated from the social-media noise. Some of these have strong data behind them. Some have promising preliminary data. One has mostly anecdote.
A peptide is a short chain of amino acids — typically fewer than 50 — that signals specific receptors or processes in the body. The body produces hundreds of endogenous peptides constantly; insulin and oxytocin are familiar examples. Therapeutic peptides are either synthetic versions of natural peptides, or analogs designed to bind the same receptors with longer half-lives or specific tissue targeting.
Peptides are not steroids and they are not "supplements" in the FDA sense. The compounds discussed below are prepared by 503A compounding pharmacies under prescription from a licensed provider; they are not FDA-approved as commercial products.
The Wolverine protocol combines BPC-157, a 15-amino-acid peptide derived from a protein found in gastric juice, with TB-500 (a synthetic fragment of thymosin beta-4). Animal studies — and there are now over 100 of them — consistently show accelerated healing of muscle, tendon, ligament, and gut tissue, with no significant toxicity findings even at high doses. The mechanism appears to involve angiogenic and anti-inflammatory effects.
The catch: there are no completed peer-reviewed randomized controlled trials in humans. Use in humans is widespread, particularly among athletes recovering from connective-tissue injuries, but the published human safety record is anecdotal rather than systematic. Anyone using BPC-157 should know they're operating on extrapolation from animal data, not human evidence.
Sermorelin is a synthetic analog of growth hormone releasing hormone (GHRH). It stimulates the pituitary to release the body's own growth hormone in a natural pulsatile pattern, rather than introducing exogenous GH directly. It was FDA-approved in 1990 for pediatric growth hormone deficiency, then withdrawn for commercial reasons (not safety) in 2008; it remains available through compounding pharmacies.
Adult use for sleep quality, recovery, and body composition is off-label but has decades of clinical use behind it. The evidence base for adult longevity outcomes specifically is limited — most adult studies focus on body composition and quality-of-life endpoints over 6–12 months, not multi-decade outcomes. The safety profile is well-characterized.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme that drops with age and is required for several longevity-relevant pathways including sirtuin activation. The Sinclair lab's work has been the major popular driver of interest in NAD+ supplementation.
Direct IV NAD+ has variable bioavailability and the systemic effects are still being characterized. Oral precursors — NMN and NR — have more controlled human studies showing reliable elevation of blood NAD+ levels, though whether that translates to clinical longevity outcomes is still an open question. The honest answer here is: the underlying biology is interesting, the clinical outcomes data is preliminary, and 5–10 years of further research will probably clarify the picture significantly.
Glutathione is the body's primary intracellular antioxidant. Levels drop with age, oxidative stress, and several specific pathologies. The case for glutathione's biological importance is unambiguous; the case for supplementation is more nuanced.
Oral glutathione has poor bioavailability — most of it is broken down in the gut. Liposomal and IV forms get higher blood levels, but whether elevated blood glutathione meaningfully raises intracellular glutathione (where it actually does its work) is contested. The strongest clinical evidence is in specific pathologies (acetaminophen overdose, certain liver diseases) rather than general wellness. Pre-cursors like N-acetylcysteine often have stronger evidence than glutathione itself.
A reasonable framework, drawn from how the evidence actually stratifies:
None of these are appropriate to start without a provider evaluation. None are substitutes for the foundational levers (sleep, exercise, body composition, blood work). And none of them have the multi-decade human longevity outcome data that lifestyle interventions have. They are tools, not magic.
Reach Peak Life's longevity protocols include the compounds discussed here, prescribed by independent providers when appropriate for the individual's goals and labs. We're upfront about which compounds have strong evidence and which are based on emerging data, and we don't market any of them as cures or guarantees.
Provider-supervised peptide and longevity protocols. Compound selection is matched to your goals and labs — not a one-size-fits-all stack.
Learn about Longevity →An A1c of 5.7 lands you in the "pre-diabetes" category — a label that often gets dismissed as not a real diagnosis. The label is misleading. The disease process driving A1c upward is already underway by the time you cross 5.7. The good news: this is the window where the trajectory is most responsive to intervention.
Hemoglobin A1c reflects the percentage of your red blood cells that have glucose attached to them. Because red blood cells live about 120 days, A1c gives you an average of your blood sugar over the past 2–3 months — much more useful than a single fasting reading, which only tells you what your glucose was that morning.
A1c of 5.7 corresponds to an estimated average glucose around 117 mg/dL. For context: a healthy non-diabetic adult typically averages somewhere in the 80–105 range. So 5.7 is not a "normal" reading that's been arbitrarily reclassified as concerning — it reflects average glucose meaningfully higher than the metabolically healthy population.
The American Diabetes Association defines:
The thresholds aren't arbitrary. They're drawn from large prospective cohorts that tracked who progressed to diabetes and who developed diabetes-related complications (retinopathy, nephropathy, cardiovascular events). The 5.7 threshold is roughly where the curves start bending — risk of progression climbs measurably above this point.
The Diabetes Prevention Program (DPP, Knowler 2002) — one of the largest interventional trials in this space — showed that adults in the pre-diabetic range had roughly an 11% per year conversion rate to type 2 diabetes without intervention. That compounds: roughly half progress to full diabetes within 5–7 years if nothing changes.
The dominant process is insulin resistance: your cells respond less efficiently to insulin, so your pancreas compensates by secreting more of it. For years, this works — fasting glucose stays normal even as insulin demand rises. The pancreas is doing extra work to keep the system in range.
Eventually the compensation starts to fail. Beta cell function declines (some of it irreversibly), insulin output can no longer keep up with resistance, and fasting glucose starts to rise. By the time you have a "real" diabetes A1c (≥ 6.5), beta cell function has typically already lost 50% of its capacity — and most of that loss is permanent.
That's why the pre-diabetic window matters: it's when you can still meaningfully alter the trajectory of beta cell health, not just manage symptoms after the damage is done.
The DPP and subsequent trials are unusually clear on what works:
A single A1c in the 5.7–6.4 range is worth a conversation with your primary care provider, ideally one that includes: a fasting insulin level (to assess insulin resistance directly via HOMA-IR), a fasting lipid panel, blood pressure check, and a frank conversation about what your individual modifiable risk factors are. Your PCP can also identify whether a referral to an endocrinologist or registered dietitian is appropriate.
This is the kind of finding where early action genuinely changes outcomes — and where waiting until the next annual physical to "see if it goes up" is often the wrong call.
Reach Peak Life's lab panels include A1c with reference values appropriate for adult metabolic health. The Longevity Score calculator includes A1c in its scoring engine and flags values in the 5.7+ range as part of the metabolic-risk screen. As always: a Reach Peak Life score is not a substitute for clinical evaluation, and significant findings should be discussed with your PCP.
A1c, fasting insulin, lipid panel, and CBC — the markers that together describe metabolic trajectory. Order direct, no clinic visit required.
Browse Lab Panels →
